Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / KPTI - Karyopharm/Antengene files application for ATG-010 in China for endometrial cancer

KPTI - Karyopharm/Antengene files application for ATG-010 in China for endometrial cancer

Karyopharm Therapeutics Inc.
Antengene has submitted an Investigational New Drug ((IND)) application for ATG-010 (selinexor, XPOVIO) being co-developed by Karyopharm Therapeutics (KPTI)  to the National Medical Products Administration ((NMPA)) in the treatment of Endometrial Cancer.The Phase 3, double-blind trial ((SIENDO)) aims to evaluate the efficacy of ATG-010 compared to placebo as maintenance therapy in patients with advanced or recurrent endometrial cancer after combination chemotherapy.Yesterday, the company filed a new drug application for ATG-010 in blood cancer in South Korea.

For further details see:

Karyopharm/Antengene files application for ATG-010 in China for endometrial cancer
Stock Information
Company Name: Karyopharm Therapeutics Inc.
Stock Symbol: KPTI
Market: NASDAQ
Website: karyopharm.com
Menu
KPTI KPTI Quote KPTI Short KPTI News KPTI Articles KPTI Message Board
Get KPTI Alerts

News, Short Squeeze, Breakout and More Instantly...